drugset / Trial / NCT06961643

Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT06961643

Phase 1 Completed 24 enrolled Shandong Suncadia Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.

Timeline

Start
2025-06-05
Primary completion
2026-01-22
Completion
2026-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-7535 Small molecule Oral

Indications